Streetbeat News

BMEA

Biomea Fusion, Inc.

Industry

Biotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Open

7.02

Mkt cap

237M

Volume

907K

High

7.11

P/E Ratio

-1.62

52-wk high

22.74

Low

6.48

Div yield

N/A

52-wk low

3.61

In Monday's pre-market session, several healthcare stocks experienced significant movements. Pasithea Therapeutics (KTTA) saw a sharp rise of 86.6%, while Assure Holdings (IONM) and Poseida Therapeutics (PSTX) also saw substantial gains. On the downside, Cogent Biosciences (COGT) and X4 Pharmaceuticals (XFOR) faced notable declines. These movements reflect changes in investor sentiment and could be driven by recent company news, market trends, or broader sector shifts.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 1:06 pm

Green Giant Inc. (GGE) shares plummeted by 37.1% in pre-market trading due to a proposed public offering. Other stocks experienced significant movement in pre-market trading, with notable gainers including NextPlay Technologies (NXTP), Onconova Therapeutics (ONTX), and Macy's (M), which received a $5.8 billion acquisition bid. Losers included Near Intelligence (NIR), which filed for Chapter 11, and Cyngn Inc. (CYN), which announced a $5 million public offering.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 12:59 pm

Biomea Fusion, Inc. (BMEA) reported positive top line data from the Phase II COVALENT-111 clinical study for BMF-219, showing a near doubling in the percentage of patients with durable HbA1c reduction in the 200 mg dose cohorts compared to the 100 mg cohorts. The results will be presented in detail at the ATTD conference in March 2024. No serious adverse events or study discontinuations have been reported to date.

Portfolio Pulse from Charles Gross

December 10, 2023 | 3:08 pm

Comtech Telecommunications Corp. (CMTL) shares dropped over 16% due to weaker-than-expected quarterly earnings, reporting adjusted earnings of 24 cents per share against estimates of 26 cents. Sales were nearly in line with expectations at $151.91 million versus $151.87 million forecasted. The stock fell to $10.45. Other stocks moved in the session, with notable gainers including Intensity Therapeutics (INTS), MBIA Inc. (MBI), and ALX Oncology Holdings (ALXO), among others. Losers included Cyngn Inc. (CYN), African Agriculture Holdings (AAGR), and Golden Heaven Group Holdings (GDHG).

Portfolio Pulse from Avi Kapoor

December 08, 2023 | 5:58 pm

Citigroup analyst Yigal Nochomovitz has reiterated a Buy rating on Biomea Fusion (NASDAQ:BMEA) and maintained a $90 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 5:17 pm

Biomea Fusion Inc (NASDAQ:BMEA) reported results from a Phase 2 study and preclinical ex-vivo human islet experiments for BMF-219, a treatment for type 2 diabetes. The study showed improved HbA1c levels in participants, with varying degrees of efficacy based on dosage and food intake. BMF-219 also demonstrated potential benefits in beta cell mass and function. Despite these findings, BMEA shares dropped 17.90% to $12.35.

Portfolio Pulse from Vandana Singh

December 08, 2023 | 4:48 pm

Biomea Fusion's stock price has declined following the announcement of long-term follow-up data from its Phase II study of BMF-219 in adults with type 2 diabetes, which was presented at WCIRDC.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 3:49 pm

Verint Systems Inc. (VRNT) reported strong third-quarter earnings, surpassing market estimates and saw its shares rise by 14%. Other stocks also moved higher, including Semtech Corporation (SMTC) after reporting earnings and guidance, and Alphabet Inc. (GOOGL) following the launch of Gemini AI. Notably, Cerevel Therapeutics Holdings, Inc. (CERE) surged after an acquisition announcement by AbbVie Inc. (ABBV).

Portfolio Pulse from Avi Kapoor

December 07, 2023 | 3:17 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. EyePoint Pharmaceuticals (EYPT) saw a substantial increase of 172.8%, while Alterity Therapeutics (ATHE) and Altimmune (ALT) also had notable gains. Conversely, NexImmune (NEXI), BioAtla (BCAB), and Vivos Therapeutics (VVOS) were among the stocks that declined.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:31 pm

Science Applications International Corporation (SAIC) reported Q3 results with a slight revenue decline but beat consensus estimates and raised FY24 guidance, causing its shares to surge by 6.9%. Other stocks also moved higher, including Hawaiian Holdings (HA) after an acquisition announcement by Alaska Air Group (ALK), and several companies like Wallbox (WBX), CleanSpark (CLSK), and Carvana (CVNA) due to various positive developments. Uber (UBER) rose after news it would join the S&P 500 index.

Portfolio Pulse from Lisa Levin

December 04, 2023 | 3:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.